APOE epsilon3 gene transfer attenuates brain damage after experimental stroke
Barry W McColl1, Ailsa L McGregor, Andrew Wong
1Wellcome Surgical Institute, Division of Clinical Neuroscience, University of Glasgow, Garscube Estate, Glasgow, UK.
Summary
Gene transfer of Apolipoprotein E (APOE) epsilon3 improved outcomes in a murine stroke model. APOE gene therapy significantly reduced brain damage, suggesting a potential stroke treatment strategy.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Apolipoprotein E (apoE) is crucial for brain lipid transport and recovery after injury.
- The APOE gene has different isoforms, with APOE epsilon3 being common.
Purpose of the Study:
- To investigate if APOE epsilon3 gene transfer enhances recovery after transient focal cerebral ischemia in mice.
- To assess the therapeutic potential of modulating brain apoE levels.
Main Methods:
- Mice received intrastriatal injections of Ad-APOE (APOE epsilon3), Ad-GFP (control), or vehicle.
- Focal cerebral ischemia was induced 3 days post-injection.
- Gene transfer efficiency and apoE levels were confirmed via protein expression and immunoreactivity.
Main Results:
- Successful gene transfer and increased brain apoE levels were observed in the Ad-APOE group.
- Ad-APOE treatment significantly reduced ischemic damage volume by approximately 50% compared to controls.
- Enhanced apoE immunoreactivity correlated with reduced brain damage.
Conclusions:
- Gene transfer of APOE epsilon3 effectively improves outcomes in a murine model of cerebral ischemia.
- Modulating brain apoE levels through gene therapy presents a promising strategy for human stroke treatment.
